Institutional shares held 3.52 Million
0 calls
0 puts
Total value of holdings $1.93M
$0 calls
$0 puts
Market Cap $113M
216,864,992 Shares Out.
Institutional ownership 1.62%
# of Institutions 6


Latest Institutional Activity in MTNB

Top Purchases

Q2 2024
Highbridge Capital Management LLC Shares Held: 10.6M ($5.54M)
Q2 2024
Towercrest Capital Management Shares Held: 1.89M ($981K)
Q2 2024
Alliance Wealth Management Group Shares Held: 1.89M ($981K)
Q2 2024
Wells Fargo & Company Shares Held: 355K ($185K)
Q2 2024
Geode Capital Management, LLC Shares Held: 2.29M ($1.19M)

Top Sells

Q2 2024
Sargent Investment Group, LLC Shares Held: 3.49M ($1.82M)
Q2 2024
Bank Of America Corp Shares Held: 48.7K ($25.3K)
Q2 2024
Trajan Wealth LLC Shares Held: 10K ($5.2K)
Q2 2024
National Wealth Management Group, LLC Shares Held: 38.3K ($19.9K)
Q2 2024
Morgan Stanley Shares Held: 46K ($23.9K)

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.


Insider Transactions at MTNB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on MTNB

Follow Matinas BioPharma Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MTNB shares.

Notify only if

Insider Trading

Get notified when an Matinas Bio Pharma Holdings, Inc. insider buys or sells MTNB shares.

Notify only if

News

Receive news related to Matinas BioPharma Holdings, Inc.

Track Activities on MTNB